MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Ambroxol treatment of primary macrophages derived from patients with GBA-associated Parkinson’s disease

    A. Kopytova, M. Nikolaev, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

    Objective: The aim was to evaluate the effectiveness of the restoration of GCase activity in macrophages from GBA-PD patients using pharmacological chaperone ambroxol. Background: Mutations…
  • 2019 International Congress

    Blood–brain barrier breakdown in an adult mouse model of Parkinson’s disease

    E. Del-Bel, F. Grano (Ribeirão Preto, Brazil)

    Objective: This study aims to evaluate the integrity of the blood-brain barrier (BBB) in parkinsonism. Background: Parkinson's disease (PD) is a neurodegenerative disorder which is…
  • 2019 International Congress

    Prospective Characterization of Genetically Confirmed X-linked Dystonia Parkinsonism Patients and their Families: A 1 year longitudinal feasibility study

    P. Acuna, J. de Guzman, N. Ganza-Bautista, J. Lagarde, C. Go, N. Sharma (Boston, MA, USA)

    Objective: A one year feasibility study for a planned prospective longitudinal study of X-linked Dystonia-Parkinsonism patients and their families in rural Philippines. Background: X-linked dystonia…
  • 2019 International Congress

    How Parkinson’s Disease Affects Value-Based Decisions

    L. Montaser-Kouhsari, R. Gerraty, A. Bakkour, D. Shohamy (New York, NY, USA)

    Objective: Parkinson’s Disease (PD) is a degenerative motor disease that causes subtle deficits in decision-making as a result of striatal dysfunction due to dopamine depletion.…
  • 2019 International Congress

    Impulse Control Disorders in a Brazilian population with Parkinson´s disease -an observational study

    B. Veiga, V. Borges, H. Ferraz, C. Aquino, C. Giacominelli, SM. Silva, S. Lestingi (São Paulo, Brazil)

    Objective: To Analyse Impulse Control Disorders (ICDs) and Related Behaviors (RB) in 36 Brazilian patients with Parkinson´s disease (PD) and compare the cognition of the…
  • 2019 International Congress

    Semantic Memory Assessment in Parkinson’s Disease

    J. Cardona, F. Marmolejo-Ramos, C. Trujillo, M. Larson (Santiago de Cali, Colombia)

    Objective: We assessed the performance of patients with a diagnosis of Parkinson’s disease (PD) in a series of semantic memory (SM) tasks including both living…
  • 2019 International Congress

    Task difficulty and the three-stimulus oddball task in patients with PD

    E. Peterson, R. Shoorangiz, R. Jones, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, R. Kuijer, T. Anderson, J. Dalrymple-Alford, B. Elias (Auckland, New Zealand)

    Objective: Examine the effect of task difficulty on event-related potentials (ERPs) in an oddball task in patients with PD. Background: In three-stimulus oddball tasks, some…
  • 2019 International Congress

    The contribution of striatal dopamine to feedforward motor control during gait initiation in Parkinson’s disease

    G. Brandt, C. Palmisano, J. Brumberg, N. Pozzi, A. Canessa, G. Pezzoli, I. Isaias, J. Volkmann (Würzburg, Germany)

    Objective: To establish the contribution of striatal dopamine to gait initiation in Parkinson’s disease. Background: Gait initiation (GI) is characterized by anticipatory postural adjustments (APAs),…
  • 2019 International Congress

    Experimental model of developing of Parkinson’s disease

    M. Tukhtamishev, F. Akhmedova (Tashkent, Uzbekistan)

    Objective: Analyzing the reserpine model of Parkinsonian syndrome Background: There are several experimental models of Parkinson's disease: reserpine, methamphetamine, 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - substances that…
  • 2019 International Congress

    Antipsychotics Use in Parkinson’s Disease and Mortality Risks

    WM. Liu, JH. Wang, HY. Chen, R. Lo (Hualien, Taiwan)

    Objective: To describe the use of antipsychotics in patients with Parkinson’s disease (PD) and study its associated mortality risks. Background: The US Food and Drug…
  • « Previous Page
  • 1
  • …
  • 142
  • 143
  • 144
  • 145
  • 146
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley